Another view of the history of antipsychotic drug discovery and development

Molecular Psychiatry

Volumn 17, Issue 12, 2012, Pages 1168-1173

  Carpenter, W T ^a   Davis, J M ^b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

antipsychotic drugs; chlorpromazine; history; psychopharmacology; schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; MEPROBAMATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AKATHISIA; COGNITION; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HISTORY OF MEDICINE; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; METHODOLOGY; NEGATIVE SYNDROME; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOLOGY; PSYCHOSIS; RELAPSE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; SCHIZOPHRENIA;

EID: 84870062983     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.121     Document Type: Review

References (56)

1. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005; 17: 113-135.
2. Sabbatini RME. The History of Shock Therapy in Psychiatry.
3. Dawson DJC, Kernohan GA, Knox SJ. Reserpine in schizophrenia. Lancet 1958; 272: 589.
4. Braslow JT. Mental Ills and Bodily Cures: Psychiatric Treatment in the First Half of the Twentieth Century. University of California Press, 1997.
5. Rees L, King GM. Cortisone in the treatment of schizophrenia. Br J Psychiatry 1952; 98: 401-403.
6. Rees L, King GM. Intensive cortisone therapy in schizophrenia. Br J Psychiatry 1956; 102: 155-159.
7. Lamb HR, Weinberger LE. The shift of psychiatric inpatient care from hospitals to jails and prisons. J Am Acad Psychiatry Law 2005; 33: 529-534.
8. Delay J, Deniker P. Le traitement des psychoses par une methode neurolytique derivee de l'hibernotherapie. Congres des medecins alienistes et neurologistes; Luxembourg; July 1952.
9. Kirkpatrick B, Fenton WS, Carpenter Jr WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32: 214-219.
10. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Williams and Wilkins: Baltimore 1969.
11. Healy D. The Creation of Psychopharmacology. Harvard University Press: Cambridge, MA, 2002.
12. Thuillier J. Ten Years that Changed the Face of Mental Illness. English edition approved by David Healy; translated by Gordon HickishMartin Dunitz: London; Blackwell Science: Malden, MA 1999.
13. Kraepelin E. Dementia Praecox and Paraphrenia. Krieger: New York, 1971, [First published, 1919].
14. Blueler E. Dementia Praecox or the Group of Schizophrenias. International Universities Press: New York, 1950, [First Published, 1911].
15. Rado S. Psychoanalysis of Behavior: The Collected Papers of Sandor Rado Vol 2. Grune and Stratton: New York, 1962.
16. Meehl PE. Primary and secondary hypohedonia. J Abnorm Psychol 2001; 110: 188-193.
17. Strauss JS, Carpenter Jr WT , Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974; 11: 61-69.
18. Peralta V, Cuest MJ. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 2001; 49: 269-285.
19. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975; 132: 1237-1245.
20. May Philip RA. Treatment of Schizophrenia: A comparative study of five treatment methods. 1st edn (Science House, New York, 1968).
21. Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997; 54: 401-407.
22. Carpenter WT. The risk of medication-free research. Schizophr Bull 1997; 23: 11-18.
23. Carpenter WT, Appelbaum PS, Levine RJ. The declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiatry 2003; 160: 356-362.
24. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-2071.
25. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010; 36: 48-70.
26. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93.
27. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010; 36: 94-103.
28. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-144.
29. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483.
30. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217-1219.
31. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A Double-Blind PET Study of First-Episode Schizophrenia. Am J Psychiatry 2000; 157: 514-520.
32. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-2574.
33. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-9240.
34. Smith A, Li M, Becker S, Kapur S. Dopamine, prediction error and associative learning: a model-based account. Network 2006; 17: 61-84.
35. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352.
36. Kane JM. The use of depot neuroleptics: clinical experience in the United States. J Clin Psychiatry 1984; 45(5 Pt 2): 5-12.
37. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999; 60(Suppl 12): 22-23.
38. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparision with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
39. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-26.
40. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry, 2003; 60: 82-91
41. Erratum in: Arch Gen Psychiatry.2003;60(7):735.
42. Spivak B, Mester R, Wittenberg N, Maman Z, Weizman A. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacol 1997; 20: 442-446.
43. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
44. Leucht S, Komossa K et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-163.
45. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
46. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K et al. CUtLASS team. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191: 14-22.
47. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165: 1420-1431.
48. Scolnick E. Program to improve cognitive functioning in patients with schizophrenia: reflections. Schizophr Res 2004; 72: 75-77.
49. Carpenter Jr WT . Clinical constructs and therapeutic discovery. Schizophr Res 2004; 72: 69-73.
50. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008; 33: 2061-2079.
51. Bergen SE, Petryshen TL. Genome-wide association studies of schizophrenia: does bigger lead to better results? Curr Opin Psychiatry 2012; 25: 76-82.
52. Allardyce J, Gaebel W, Zielasek J, van Os J. Deconstructing Psychosis Conference February 2006: the validity of schizophrenia and alternative approaches to the classification of psychosis. Schizophr Bull 2007; 33: 863-867.
53. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005; 31: 5-19.
54. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull 2011; 37: 250-254.
55. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: The NIMH. Res Domain Criteria Project Schizophr Bull 2010; 36: 1061-1062.
56. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748-751.